SCHOTT Pharma AG & Co. KGaA (1SXP.F)
EUR 23.72
(0.08%)
EUR 23.72
(0.08%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 227.64 Million EUR | 5.01% |
| 2022 | 203.08 Million EUR | 40.56% |
| 2021 | 147.47 Million EUR | 23.74% |
| 2020 | 125.21 Million EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 72.63 Million EUR | 38.45% |
| 2024 Q2 | 45.14 Million EUR | -39.96% |
| 2024 Q3 | 76.08 Million EUR | 71.8% |
| 2023 Q2 | 69.1 Million EUR | 21.04% |
| 2023 FY | - EUR | 5.01% |
| 2023 Q3 | 55.15 Million EUR | -20.18% |
| 2023 Q1 | 57.09 Million EUR | 23.49% |
| 2023 Q4 | 57.71 Million EUR | 4.64% |
| 2022 Q4 | 46.23 Million EUR | 0.0% |
| 2022 FY | - EUR | 40.56% |
| 2021 FY | - EUR | 23.74% |
| 2020 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Carl Zeiss Meditec AG | 502.77 Million EUR | 54.722% |
| Fielmann Aktiengesellschaft | 403.8 Million EUR | 43.625% |
| Gerresheimer AG | 400.56 Million EUR | 43.169% |
| Sartorius Aktiengesellschaft | 920.1 Million EUR | 75.259% |
| Sartorius Aktiengesellschaft | 920.1 Million EUR | 75.259% |